Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects
dc.contributor.author | Attia, Noha | |
dc.contributor.author | Mashal, Mohamed | |
dc.contributor.author | Puras Ochoa, Gustavo | |
dc.contributor.author | Pedraz Muñoz, José Luis | |
dc.date.accessioned | 2021-07-09T16:28:05Z | |
dc.date.available | 2021-07-09T16:28:05Z | |
dc.date.issued | 2021-06-07 | |
dc.identifier.citation | Pharmaceutics 13(6) : (2021) // Article ID 843 | es_ES |
dc.identifier.issn | 1999-4923 | |
dc.identifier.uri | http://hdl.handle.net/10810/52263 | |
dc.description.abstract | The cell-based approach in gene therapy arises as a promising strategy to provide safe, targeted, and efficient gene delivery. Owing to their unique features, as homing and tumor-tropism, mesenchymal stem cells (MSCs) have recently been introduced as an encouraging vehicle in gene therapy. Nevertheless, non-viral transfer of nucleic acids into MSCs remains limited due to various factors related to the main stakeholders of the process (e.g., nucleic acids, carriers, or cells). In this review, we have summarized the main types of nucleic acids used to transfect MSCs, the pros and cons, and applications of each. Then, we have emphasized on the most efficient lipid-based carriers for nucleic acids to MSCs, their main features, and some of their applications. While a myriad of studies have demonstrated the therapeutic potential for engineered MSCs therapy in various illnesses, optimization for clinical use is an ongoing challenge. On the way of improvement, genetically modified MSCs have been combined with various novel techniques and tools (e.g., exosomes, spheroids, 3D-Bioprinting, etc.,) aiming for more efficient and safe applications in biomedicine. | es_ES |
dc.description.sponsorship | Authors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the intellectual and technical assistance. The Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16); the Spanish Ministry of Science and Innovation (GrantsPID2019-106199RB-C21). | es_ES |
dc.language.iso | spa | es_ES |
dc.publisher | MDPI | es_ES |
dc.relation | info:eu-repo/grantAgreement/MCIU/PID2019-106199RB-C21 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | non-viral gene delivery | es_ES |
dc.subject | 3D-bioprinting | es_ES |
dc.subject | transfection | es_ES |
dc.subject | mesenchymal stem cell | es_ES |
dc.subject | cell therapy | es_ES |
dc.subject | gene therapy | es_ES |
dc.subject | niosome | es_ES |
dc.subject | COVID-19 | es_ES |
dc.title | Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2021-06-24T14:11:40Z | |
dc.rights.holder | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1999-4923/13/6/843 | es_ES |
dc.identifier.doi | 10.3390/pharmaceutics13060843 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | |
dc.departamentoeu | Farmazia eta elikagaien zientziak |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).